Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
| Autor: | Rudolf Wallmann, Hannah Marchi, Tatjana Becker, Rohit Sekhri, Raphael Meixner, Vera Kolatzki, Karlo Huenerbein, Kai Wille, Martin Griesshammer, Parvis Sadjadian, Christiane Fuchs |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Risk medicine.medical_specialty Ruxolitinib Skin Neoplasms Lymphoma Mutation Missense Gastroenterology Polycythemia vera Internal medicine Nitriles Chi-square test Humans Hydroxyurea Medicine Myelofibrosis Polycythemia Vera Cytoreductive therapy Aged Proportional Hazards Models Retrospective Studies Secondary malignancy Aged 80 and over Hematology business.industry Incidence Significant difference Neoplasms Second Primary General Medicine Janus Kinase 2 Middle Aged medicine.disease Non-melanoma skin carcinomas Cytoreductive Therapy Non-melanoma Skin Carcinomas Secondary Malignancy Log-rank test Pyrimidines Primary Myelofibrosis Pyrazoles Original Article Female business Follow-Up Studies medicine.drug |
| Zdroj: | Ann. Hematol., DOI: 10.1007/s00277-021-04647-0 (2021) Annals of Hematology |
| DOI: | 10.1007/s00277-021-04647-0 |
| Popis: | Recently, there has been increased concern about a risk of secondary malignancies (SM) occurring in myelofibrosis (MF) patients receiving ruxolitinib (RUX). In polycythemia vera (PV), on the other hand, only limited data on the risk of SM under RUX treatment are available. To investigate the association between RUX therapy in PV and SM, we conducted a retrospective, single-center study that included 289 PV patients. RUX was administered to 32.9% (95/289) of patients for a median treatment duration of 48.0 months (range 1.0–101.6). Within a median follow-up of 97 months (1.0–395.0) after PV diagnosis, 24 SM occurred. Comparing the number of PV patients with RUX-associated SM (n = 10, 41.7%) with the 14 (58.3%) patients who developed SM without RUX, no significant difference (p = 0.34, chi square test) was found. No increased incidences of melanoma, lymphoma, or solid “non-skin” malignancies were observed with RUX (p = 0.31, p = 0.60, and p = 0.63, respectively, chi square test). However, significantly more NMSC occurred in association with RUX treatment (p = 0.03, chi-squared test). The “SM-free survival” was not significantly different by log rank test for all 289 patients (p = 0.65), for the patients (n = 208; 72%) receiving cytoreductive therapy (p = 0.48) or for different therapy sequences (p = 0.074). In multivariate analysis, advanced age at PV diagnosis (HR 1.062 [95% CI 1.028, 1.098]) but not administration of RUX (HR 1.068 [95% CI 0.468, 2.463]) was associated with an increased risk for SM (p = 0.005). According to this retrospective analysis, no increased risk of SM due to RUX treatment could be substantiated for PV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|